PRMT5 is an actionable target in CDK4/6 inhibitor-resistant ER plus /Rb-deficient breast cancer
Chang-Ching Lin,Tsung-Cheng Chang,Yunguan Wang, Yanfeng Zhang,Andrew Lemoff,Yisheng V. Fang,He Zhang,Dan Ye,Isabel Soria-Bretones,Alberto Servetto,Kyung-Min Lee, Xuemei Luo, Joseph J. Otto,Hiroaki Akamatsu,David W. Cescon,Lin Xu,Yang Xie,Joshua T. Mendell,Ariella B. Hanker,Carlos L. Arteaga CANCER RESEARCH(2023)
AI 理解论文
溯源树
样例